Dengue virus type 4 nonstructural protein 4B (NS4B) or Dengue virus type 4 envelope protein (E protein) (DENV-4 NS4B or DENV-4 E protein)

The term "Dengue virus type 4 immunity" encompasses the multifaceted immune response targeted at DENV-4, widely mediated by neutralizing antibodies against the envelope (E) protein and T-cell responses against nonstructural proteins such as NS3, NS4B, and NS5[1][2][5][6][7][8]. NS4B, a membrane-bound nonstructural protein, is a validated antiviral drug target due to its critical role in evading host interferon responses and supporting viral replication[1][2][8]. The E protein, especially domain III, contains receptor recognition sites and is the primary antigenic determinant for neutralizing antibody responses and vaccine development[6][7]. Monoclonal antibodies (e.g., DV4-E88) and small molecules are being developed to target these proteins, with safety challenges arising from the potential of antibody-dependent enhancement in the context of non-neutralizing or cross-reactive antibodies[3][6]. Thus, the relevant molecular targets underlying "Dengue virus type 4 immunity" are the DENV-4 NS4B and E proteins, which are central for antiviral intervention and as biomarkers for disease and therapeutic efficacy.

Other names

NS4B protein (DENV-4 NS4B)Envelope protein (DENV-4 E protein)DENV-4 nonstructural protein 4BDENV-4 E protein DIII

Drugs targeting these proteins exhibit mechanisms such as neutralization of viral particles (antibodies against E protein, DIII) and blockade of viral immune evasion (NS4B inhibitors restore interferon signaling).